The paper introduces macropinocytosis-mediated recyclable LYTACs (McR-TACs), a receptor-independent approach to degrading extracellular and membrane proteins. The design is meant to exploit macropinocytosis so that the degrader is recycled and can act on its target across multiple cycles, addressing the reliance of conventional lysosome-targeting chimeras on specific cell-surface receptors. The title positions the work within the extracellular targeted protein degradation field.
Karadakic, Barnett and colleagues used 100% US Medicare fee-for-service claims data to compare survival associations after mRNA COVID-19, adenoviral COVID-19, and influenza vaccination before versus after ICI initiation, among 121,676 beneficiaries starting systemic anticancer therapy, including 10,824 ICI users.
Why it matters: The study compares mRNA COVID-19, adenoviral COVID-19, and influenza vaccines in parallel in the same dataset, a key control for isolating mRNA-specific effects.
China's NMPA has granted conditional approval to Weiliduomab injection (brand name Weiketuo), making it the first domestically developed BCMA×CD3 bispecific antibody approved in China. Fosun Pharma's subsidiary Yaoyou Pharmaceutical, which in May 2026 licensed exclusive rights for clinical development and commercialization in mainland China, Hong Kong, Macau and Taiwan, holds the marketing authorization. The drug treats adults with relapsed or refractory multiple myeloma who have received at least three prior lines including a proteasome inhibitor, an immunomodulator and an anti-CD38 antibody. The approval rests on the Phase 2 GR1803002 trial, showing an ORR of 79.1% and an MRD negativity rate of 96.72% among patients achieving CR or sCR; further studies in RRMM are ongoing.
First-line sunvozertinib extended median progression-free survival to 10.3 months versus 7.5 months with carboplatin-pemetrexed in advanced nonsquamous NSCLC with EGFR exon 20 insertion mutations (hazard ratio 0.65; P<0.001), in a phase 3 trial of 324 patients. Objective response was 58.9% versus 31.1%, with median duration of response of 11.2 versus 7.1 months. The findings support moving sunvozertinib, already accelerated-approved in later lines, into first-line use.
China's NMPA approved Tong Yuan Kang's aumolertinib-deuterated EGFR-TKI TY-9591 (Cadaza, dextromethorphan aitinib mesylate tablets) on August 27 via priority review for first-line treatment of adults with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletion or L858R mutation accompanied by CNS metastases. The company says structural optimization improves pharmacokinetics, reduces toxic metabolite formation, and showed positive efficacy and safety signals in brain metastasis and EGFR L858R populations.
In a randomized, double-blind, active-controlled phase III trial in high-risk melanoma, Moderna's personalized neoantigen vaccine mRNA-4157 combined with pembrolizumab significantly improved both recurrence-free survival and distant metastasis-free survival over pembrolizumab alone. The article calls it the first personalized neoantigen cancer vaccine to succeed in a large randomized phase III trial. Tumor sequencing selects up to 34 patient-specific neoantigens; the mRNA vaccine is delivered by LNP into dendritic cells, activating endogenous T cells and inducing epitope spreading.
Why it matters: The article links the phase III randomized results to the vaccine's technical route of up to 34 neoantigens, LNP delivery, and epitope spreading.
Hutchmed's Class 1 innovative drug, voragligratinib tartrate tablets (HMPL-453), was approved in China on August 28 for adults with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma harbouring FGFR2 fusion or rearrangement who have received prior systemic therapy. The drug is the first domestically developed highly selective small-molecule FGFR1/2/3 inhibitor.
The FDA has granted early approval to Daraxonrasib, the first RAS(ON) inhibitor cleared anywhere in the world, for pancreatic cancer. The decision gives patients with KRAS-mutation-driven pancreatic cancer, a disease with a 5-year relative survival rate of just 3%, a targeted therapy option after years when no targeted drug was available. The approval moves pancreatic cancer treatment from a chemotherapy-dominated approach toward precision targeting.
The US FDA has approved Revolution Medicines' oral pan-RAS inhibitor Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not suited to multi-drug combination systemic therapy. The approval follows overall survival benefit shown in a phase 3 trial. Rasonque works through a molecular-glue ternary complex strategy targeting RAS, a target once considered undruggable.
Integrating protein structures with mutation data from 139,818 patients yields functional maps of mutations for 173 cancer genes across more than 18 tumor types. Oncogenic mutations cluster in significantly mutated regions tied to key functions, such as DNA-binding domains in FOXA1 and ligand-binding sites in ERBB2, while in genes like TP53 they follow three-dimensional structural constraints. The work offers a proteo-genomic framework for clinical interpretation of mutations in precision medicine.
The FDA approved Revolution Medicines' daraxonrasib (RMC-6236, brand name Rasonque) on August 26 for patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or are not suited to multiple systemic therapies. The oral RAS(ON) multi-selective non-covalent inhibitor blocks interactions between wild-type and mutant RAS(ON) proteins and downstream effectors, and the FDA said the approval came 6.5 months ahead of schedule.
The US FDA has approved Revolution Medicines' pan-RAS inhibitor daraxonrasib, brand name Rasonque, for previously treated metastatic pancreatic cancer (PDAC). The drug, the company's lead pipeline asset and the first RAS(ON) inhibitor approved worldwide, is active against G12, G13, Q61 and wild-type RAS. Late-stage trials are already underway in first-line, second-line and adjuvant pancreatic cancer settings.
The FDA approved Revolution Medicines' Rasonque (daraxonrasib), the first RAS(ON) inhibitor to reach the market, on August 26, months ahead of expectation. The once-daily tablet targets multiple forms of RAS protein, a key driver of tumor growth in most pancreatic cancer patients, and offers a new treatment option for the most common form of advanced pancreatic cancer, which arises from cells lining the pancreatic ducts.
The FDA approved Revolution Medicines' first-in-class RAS inhibitor Rasonque (daraxonrasib) on August 26 for adults with metastatic pancreatic ductal adenocarcinoma who have received at least one prior systemic therapy or are not suited for multi-drug systemic treatment. It is the first RAS-targeted therapy for the most common type of pancreatic cancer. The drug was reviewed under the FDA commissioner's national priority voucher pilot programme, and approval came one month after the application was accepted, 6.5 months ahead of the PDUFA goal date.
The US FDA has approved Revolution Medicines' daraxonrasib (Rasonque) for pancreatic adenocarcinoma patients who have received at least one prior systemic therapy or are not eligible for multiagent systemic therapy. It is the first broadly active RAS-targeted inhibitor to reach market, unlike the KRAS G12C-specific inhibitors sotorasib (Lumakras) and adagrasib (Krazati), which are approved only in NSCLC and colorectal cancer subsets.
FDA approved Revolution Medicines' daraxonrasib (Rasonque) for pancreatic ductal adenocarcinoma, making it the first targeted therapy in the new RAS(ON) inhibitor class and the first new cancer drug cleared under the commissioner's national priority review voucher initiative. Revolution Medicines (NASDAQ:RVMD) is launching the drug immediately at a WAC of $39,800 for a 30-day supply.
The FDA approved daraxonrasib, brand name Rasonque, from Revolution Medicines as a second-line treatment for advanced pancreatic cancer, making it the first drug to attack a genetic cause of the disease. In the supporting trial, patients on Rasonque achieved median overall survival of 13.2 months versus 6.7 months on standard chemotherapy. Clinicians described it as the biggest development in pancreatic cancer in decades.
A Science paper shows that tumor-local PGE2 drives cancer-associated cachexia through the vagus nerve in LKB1 (STK11)-mutant lung adenocarcinoma, explaining why high-fat diets may backfire in this subtype. BioArtMED reviews the study and notes that circulating inflammatory factors such as IL-6 and GDF15 were previously seen as the main cachexia drivers, but they cannot explain the differing responses of specific mutation subtypes to dietary intervention.
Why it matters: The review explains the Science paper's mechanism of tumor-local PGE2 driving cachexia via the vagus nerve, giving an experimental answer to why high-fat diets may worsen outcomes in LKB1-mutant lung adenocarcinoma.
The US FDA approved a new indication for tislelizumab on August 26, 2026, combining it with zanidatamab plus chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). The approval covers patients regardless of PD-L1 expression and is the first approved regimen pairing a HER2 bispecific antibody with a PD-1 inhibitor. It rests on the HERIZON-GEA-01 trial, published in the New England Journal of Medicine and presented orally at the 2026 ASCO annual meeting.
